Medicines Patent Pool

Medicines Patent Pool

Interactive Data Dashboards

Track the HIV & TB response

Live indicators, province breakdowns and downloadable data.

  • Pretoria company aims to lead SA in making key TB drug ingredients

    Though several South African companies are producing HIV and TB medicines, the active ingredients that go into these medicines are usually imported from India or China. Now, a local company is planning to break new ground by making the active ingredients for two important TB medicines in Pretoria. Catherine Tomlinson zooms in on the company’s…

    ·

  • HIV prevention shots and vaginal rings – this is why SA pilots have not yet started

    Last year Spotlight reported that pilot projects testing out a new HIV prevention injection and a vaginal ring in South Africa would start early in 2023. Yet, as delegates gathered for the SA AIDS Conference in Durban last week, those pilots hadn’t yet started. Alicestine October and Elri Voigt have the latest on the state…

    ·

  • First HIV prevention injection approved in SA

    The South African Health Products Regulatory Authority has authorised an injection containing the antiretroviral cabotegravir for use to prevent HIV infection, according to drugmaker ViiV Healthcare. Laura Lopez Gonzalez reports.

    ·

  • SA expected to begin piloting HIV prevention shot in early 2023

    South Africa is expected to begin piloting the every-other-month HIV prevention shot early next year, according to the international medicine financing initiative Unitaid. New modelling shows that the injection could prevent as many as 52 000 new HIV infections in the next two decades. But to be cost-effective in South Africa, the research argues, the…

    ·

  • Vaccine partnership with US government boosts prospects for local production

    Earlier this month Cape Town-based vaccine company Afrigen announced a formal collaboration with the United States National Institute of Allergy and Infectious Diseases’ (NIAID’s) Vaccine Research Centre. Catherine Tomlinson unpacks what this deal may mean for local production of vaccines for COVID-19 and other diseases.

    ·

  • SA company gearing up to make API

    While various medicines are produced in South Africa, the active pharmaceutical ingredients going into these medicines are mostly still imported. Catherine Tomlinson reports on a local company that is trying to change that – starting with active pharmaceutical ingredients for tuberculosis and COVID-19 medicines.

    ·

  • New licenses could spark manufacture of COVID-19 pills in Africa

    Pharmaceutical companies Merck and Pfizer recently announced early results from clinical trials showing that two new antiviral medicines are highly effective in reducing COVID-19 deaths and hospitalisation. The Medicines Patent Pool then announced licensing deals with both companies that will allow for generic versions of the two drugs to be produced. Catherine Tomlinson unpacks the…

    ·

  • High hopes for deal to unlock local COVID-19 vaccine manufacturing

    On Monday President Cyril Ramaphosa announced that South Africa will host the first World Health Organization-backed COVID-19 mRNA vaccine Technology Transfer Hub – an initiative designed to get the production of mRNA vaccines off the ground in Africa. Parties involved in the hub expect to hear as early as next week whether pharmaceutical companies with…

    ·

  • Breakthrough hepatitis C medicines remain in regulatory limbo

    Over the last decade the treatment of hepatitis C, a virus that can infect and damage the liver, has been revolutionised by a new class of medicines called direct acting antivirals. Catherine Tomlinson investigates the regulatory obstacles that are limiting access to these breakthrough medicines in South Africa.

    ·

  • Op-ed: President Ramaphosa should support the COVID-19 IP pool

    Having pressed the imperative of equitable global sharing of COVID-19 health products, President Ramaphosa must now declare support for the Intellectual Property Pool for COVID-19, argues Professor Yousuf Vawda & Professor Brook K Baker.

    ·